China $1.8 Billion Jiangsu Sinopep-Allsino Biopharmaceutical Fined $6.6 Million & Issued with Delisting Warning for Inflating Revenue ($4.2 Million) & Profit ($3.6 Million) in 2021 Which Also Allowed Company to Issue $60 Million Convertible Bonds in 2023, Senior Executives Fined from $209,000 to $2.5 Million with ex-Vice Chairman & Actual Controller Dezhong Zhao Fined $2.5 Million (CNY 18 Million), Founded in 2009 by Zi Quan Tong, IPO on Shanghai Stock Exchange in 2021
23rd July | Hong Kong
China Jiangsu Sinopep-Allsino Biopharmaceutical ($1.8 billion market value) has been fined $6.6 million & issued with delisting warning for inflating revenue ($4.2 million) & profit ($3.6 million) in 2021, which also allowed company to issue $60 million convertible bonds in 2023. Senior executives were fined from $209,000 to $2.5 million with ex-Vice Chairman & actual controller Dezhong Zhao fined $2.5 million (CNY 18 million). Jiangsu Sinopep-Allsino Biopharmaceutical was founded in 2009 by Zi Quan Tong, and IPO on Shanghai Stock Exchange in 2021. Jiangsu Sinopep-Allsino Biopharmaceutical – Sinopep is a trusted CDMO specializing in end-to-end CMC development and cGMP manufacturing of peptide and oligonucleotide APIs for NCEs, from early-phase development to commercialization. Since 2009, Sinopep has passed four U.S. FDA inspections and adheres strictly to FDA/ICH guidelines. Our expertise covers process and analytical method development/validation, stability studies, and regulatory support for global filings (IND/NDA). Beyond NCEs, we are the top global supplier of Semaglutide, Tirzepatide, and Liraglutide, leading in export volume. With one of the world’s largest and most flexible production capacities, Sinopep supports projects from milligram-scale discovery to 200+ kg commercial batches. By prioritizing early-phase CMC readiness—including Phase 3-ready packages by Phase 2b—we accelerate timelines for fast-track and breakthrough therapies.
“ China $1.8 Billion Jiangsu Sinopep-Allsino Biopharmaceutical Fined $6.6 Million & Issued with Delisting Warning for Inflating Revenue ($4.2 Million) & Profit ($3.6 Million) in 2021 Which Also Allowed Company to Issue $60 Million Convertible Bonds in 2023, Senior Executives Fined from $209,000 to $2.5 Million with ex-Vice Chairman & Actual Controller Dezhong Zhao Fined $2.5 Million (CNY 18 Million), Founded in 2009 by Zi Quan Tong, IPO on Shanghai Stock Exchange in 2021 “
China $1.8 Billion Jiangsu Sinopep-Allsino Biopharmaceutical Fined $6.6 Million & Issued with Delisting Warning for Inflating Revenue ($4.2 Million) & Profit ($3.6 Million) in 2021 Which Also Allowed Company to Issue $60 Million Convertible Bonds in 2023, Senior Executives Fined from $209,000 to $2.5 Million with ex-Vice Chairman & Actual Controller Dezhong Zhao Fined $2.5 Million (CNY 18 Million), Founded in 2009 by Zi Quan Tong, IPO on Shanghai Stock Exchange in 2021
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2025 Investment Day
- March - Hong Kong
- March - Singapore
- July - Hong Kong
- July - Singapore
- Sept- Hong Kong
- Sept - Singapore
- Oct- Hong Kong
- Nov - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit
